Advertisement

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)

  • Luis Baez-Vallecillo
  • Akshara S. Raghavendra
  • Kenneth R. Hess
  • Carlos H. Barcenas
  • Stacy L. Moulder
  • Debu Tripathy
  • Vicente Valero
  • Rashmi K. MurthyEmail author
Epidemiology

Abstract

Purpose

Lapatinib (L) is approved in combination with capecitabine or letrozole for patients with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC). However, there is no efficacy data of L in patients who received prior pertuzumab (P) and ado-trastuzumab emtansine (T-DM1), now included as standard first- and second-line therapies, respectively. The goal of this study was to assess the efficacy of L in a contemporary patient population that received prior P and/or T-DM1.

Methods

We identified patients with HER2-positive MBC who received L (n = 520) between 2003 and 2017 at MD Anderson Cancer Center and selected a target cohort who received L after prior P or T-DM1 (n = 43) with the remaining included in the comparison cohort (n = 477). We evaluated outcome measures including clinical benefit rate (CBR), best tumor response (BTR), duration on L, and time to progression (TTP). Survival analyses used Kaplan–Meier statistics.

Results

CBR was 28% (95% CI 10–32) for the target cohort and 40% (95% CI 36–45) for the comparison cohort. The median duration on L was 5 months (95% CI 3.0–9.0) in the target cohort and 6.7 months (5.9–8.0) in the comparison cohort. In both cohorts, the median time to progression (TTP) and overall survival (OS) were longer in patients with de novo metastatic disease compared to patients with disease recurrence.

Conclusion

L-based therapy is an active therapeutic option and remains a viable option for HER2 + MBC after prior trastuzumab, P and/or T-DM1.

Keywords

Lapatinib Trastuzumab Pertuzumab T-DM1 HER2 Breast cancer Metastatic 

Notes

Author contributions

Design/conception: LB, VV, RM. Data collection: LB, AR. Statistical analysis: KH. Data interpretation: All authors. Manuscript writing: All authors.

Funding

The database used for this work is supported by the Breast Medical Oncology departmental funds at MD Anderson Cancer Center. KR Hess was supported by the NIH/NCI under award number P30CA016672 and used the Biostatistics Resource Group shared resource.

Compliance with ethical standards

Conflict of interest

Luiz Baez-Vallecillo, Akshara S. Raghavendra, Kenneth R. Hess, Carlos H. Barcenas, and Vicente Valero report no conflict of interest relevant to this work. Stacy L. Moulder serves or has served as a consultant for Novartis, Oncothyreon, Pfizer, and Immunogenics. Debu Tripathy serves as a consultant for Novartis and Pfizer, and also receives funding from Novartis. Rashmi K. Murthy receives research funding from Cascadian therapeutics, Daiichi Sankyo, Gnentech, and Pfizer (all in research support paid to the institution).

Ethical approval

This article does not contain any studies with human participants or animals.

Informed consent

This study was approved by the institutional review board at MD Anderson Cancer Center, and waivers for obtaining informed consent were granted.

References

  1. 1.
    Yarden Y et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11):3341–3351CrossRefGoogle Scholar
  2. 2.
    Slamon DJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefGoogle Scholar
  3. 3.
    Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRefGoogle Scholar
  4. 4.
    Slamon D et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283CrossRefGoogle Scholar
  5. 5.
    Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684CrossRefGoogle Scholar
  6. 6.
    Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefGoogle Scholar
  7. 7.
    Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743CrossRefGoogle Scholar
  8. 8.
    Blackwell KL et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124–1130CrossRefGoogle Scholar
  9. 9.
    Blackwell KL et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592CrossRefGoogle Scholar
  10. 10.
    Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119CrossRefGoogle Scholar
  11. 11.
    Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471CrossRefGoogle Scholar
  12. 12.
    Schneeweiss A et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278–2284CrossRefGoogle Scholar
  13. 13.
    Gianni L et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32CrossRefGoogle Scholar
  14. 14.
    Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791CrossRefGoogle Scholar
  15. 15.
    Esteva FJ et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800–1808CrossRefGoogle Scholar
  16. 16.
    Burstein HJ et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5): 965–972CrossRefGoogle Scholar
  17. 17.
    Bachelot T et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71CrossRefGoogle Scholar
  18. 18.
    Lin NU et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459CrossRefGoogle Scholar
  19. 19.
    Lin NU et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12):1993–1999CrossRefGoogle Scholar
  20. 20.
    Amiri-Kordestani L et al (2014) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20(17):4436–4441CrossRefGoogle Scholar
  21. 21.
    Dieras V et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732–742CrossRefGoogle Scholar
  22. 22.
    Krop IE et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689–699CrossRefGoogle Scholar
  23. 23.
    Krop IE et al (2017) Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18(6):743–754CrossRefGoogle Scholar
  24. 24.
    Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRefGoogle Scholar
  25. 25.
    Hammond ME et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefGoogle Scholar
  26. 26.
    Moulder SL et al (2017) Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer ResGoogle Scholar
  27. 27.
    Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E (2018) Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:880–888CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Cancer Medicine – Hematology/Oncology Fellowship ProgramThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Division of Cancer Medicine, Department of Breast Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations